Company intelligence / Profile preview
RetinalGenix Technologies
Apollo Beach, Florida, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
RetinalGenix is developing therapeutic drugs RTG-2023 for dry AMD and RTG-2024 for Alzheimer's disease/dementia, while also advancing diagnostic imaging devices for early disease detection through retinal screening.
- Therapeutic areas
- CardiovascularNeurologyOphthalmologyMetabolic Disorders
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
LabCorp
Beyond the preview
Go deeper on RetinalGenix Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RetinalGenix Technologies.